# US 2012/0251826 A1 · Process for the preparation of darunavir

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251826 A1
- Document ID: US20120251826A1
- Status: Published application
- Kind: A1
- Application number: 13/496,642
- Filed: 2010-09-16
- Published: 2012-10-04
- Earliest claimed: 2009-09-17
- Inventors: Siva Rama Prasad Vellanki; Arabinda Sahu; Aravind Kumar Katukuri; Vikram Vanama; Satishbabu Kothari; Venkata Suryanarayana Ponnekanti; Debashish Datta
- Web page: https://patentgrep.com/patent/US20120251826A1

## CPC

- C07D 493/04: Ortho-condensed systems
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- Y10T 428/2982: Particulate matter [e.g., sphere, flake, etc.]
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

A process for the preparation of Darunavir comprises the reacting of 4-amino-N-(2R,3S) (3-amino-2-hydroxy-4-phenylbutyl)-N-isobutyl-benzenesulfonamide with (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol derivative in N-methyl-2-pyrrolidinone and isolating the resulting Darunavir. The process yields Darunavir with a very low level of the difuranyl impurity.

## Claims

### Claim at position 1

-23. (canceled)

### Claim 24

A process for the preparation of amorphous Darunavir containing less than 0.1% of the difuranyl impurity comprising the steps of:
a) coupling the compound of formula 4 with (3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-01 derivative (5) in a solvent to obtain Darunavir,
b) optionally converting the Darunavir to Darunavir solvate,
c) dissolving the Darunavir or Darunavir solvate in a solvent, and
d) isolating amorphous Darunavir.

### Claim 25 (depends on 24)

The process according to claim 24, wherein at least one of the solvents used in step a), step b) or step c) is selected as follows:
the solvent used in step a) is selected from the group consisting of Nmethyl-2-pyrrolidinone (NMPO), N,N-dimethylformamide, ethyl acetate, tetrahydrofuran, acetonitrile, dioxane, methylene dichloride and mixture thereof;
the solvent used in step b) is selected from the group consisting of methanol, ethanol, isopropanol, ethyl acetate, tetrahydrofuran, acetonitrile, dioxane, methylene dichloride and mixtures thereof; and
the solvent used in step c) is selected from the group consisting of dichloromethane, chloroform, carbon tetrachloride, dichloroethane, tetrahydrofuran, methanol, ethanol, isopropyl alcohol, acetonitrile, ethyl acetate and mixtures thereof.

### Claim 26

A process for the preparation of Darunavir containing less than 0.1% of the difuranyl impurity, comprising coupling the compound of formula 4 with (3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-ol derivative (5) in N-methyl-2 pyrrolidinone (NMPO)

### Claim 27

A process for the preparation of amorphous Darunavir comprising the steps of:
a) dissolving Darunavir in an organic solvent,
b) removing the solvent,
c) optionally adding a hydrocarbon solvent, and
d) isolating amorphous Darunavir.

### Claim 28 (depends on 27)

The process according to claim 27, wherein at least one of the solvents used in step a) or step c) is selected as follows:
the organic solvent used in step a) is selected from the group consisting of dichloromethane, dichloroethane, chloroform, carbon tetrachloride, tetrahydrofuran, methanol, ethanol, isopropyl alcohol, acetonitrile, ethyl acetate and mixtures thereof; and
the hydrocarbon solvent used in step c) is selected from the group consisting of n-hexane, n-heptane, cyclohexane, diethyl ether, petroleum ether, methyl tert-butyl ether, octane and toluene.

### Claim 29

Darunavir ethanolate or amorphous Darunavir having a purity of more than 99.5% and containing less than 0.08% of the difuranyl impurity.

### Claim 30 (depends on 29)

Amorphous Darunavir according to claim 29 having a median particle size (D50) of less than 50 micrometers and a D90 value of less than 200 micrometers.

### Claim 31

A process for the preparation of amorphous Darunavir, which comprises:
a) providing a solution, suspension or dispersion of Darunavir or Darunavir solvate, either alone or in combination with one or more pharmaceutically acceptable carriers, in a solvent; and
b) removing the solvent from the solution to provide the desired amorphous Darunavir.

### Claim 32 (depends on 24)

The process according to claim 24, wherein the amorphous Darunavir is isolated by one of the group consisting of distillation, evaporation, spray drying, freeze drying, lyophilisation or agitated thin film drying (ATFD).

### Claim 33 (depends on 27)

The process according to claim 27, wherein the amorphous Darunavir is isolated by one of the group consisting of distillation, evaporation, spray drying, freeze drying, lyophilisation or agitated thin film drying (ATM).

### Claim 34 (depends on 31)

The process according to claim 31, wherein the solvent is removed by one of the group consisting of distillation, evaporation, spray drying, freeze drying, lyophilisation or agitated thin film drying (ATFD).

### Claim 35

A pharmaceutical composition of amorphous Darunavir or the pharmaceutically acceptable salt or solvate thereof containing less than 0.1% of the difuranyl impurity.
